Cagrinilitide 5mg / Semaglutide 5mg

Cagrilintide 5 mg / Semaglutide 5 mg — Research Material (RUO)

This research material combines cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist. Amylin analogs have been shown to influence gastric emptying and satiety signaling pathways via central and peripheral mechanisms (Hay et al., Diabetes, 2015). Semaglutide is a GLP-1 receptor agonist extensively characterized for its receptor specificity, prolonged half-life via albumin binding, and incretin-mediated effects on glucose and appetite pathways (Marso et al., N Engl J Med, 2016; Wilding et al., N Engl J Med, 2021). Investigational studies have evaluated combined amylin and GLP-1 receptor pathway activation for synergistic metabolic signaling (Lau et al., Lancet, 2021). This material is intended strictly for in-vitro or laboratory research use and is not for human consumption.